Anticoagulant Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial

Shao-Wei Lo, MD, MPH[1], Darae Ko, MD, MSc[2,3,4], Dae Hyun Kim, MD, MPH, ScD[2,5], Long H. Ngo, PhD[6], Daniel E Singer, MD[1,7], Sachin J Shah, MD, MPH[1,7,8]

1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
2. Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA
3. Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA
4. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
5. Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
6. Department of Medicine, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
7. Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
8. Center for Aging and Serious Illness, Massachusetts General Hospital, Boston, Massachusetts, USA.

Contact
Sachin J Shah, MD, MPH
Massachusetts General Hospital
100 Cambridge St, Suite 1600
Boston, MA 02114
sshah@mgh.harvard.edu

Article type: Brief Report
Table/Figure: 1
Words: 1000
References: 10

ABSTRACT

Background: The ARTESIA trial showed apixaban reduced the relative hazard of stroke/systemic embolism in subclinical atrial fibrillation (SCAF; 6 min-24 hr) by 37%, but did not report absolute risk reduction (ARR). The reported Kaplan-Meier analysis and incidence rate reduction did not account for the competing risk of death or 24-hour AF events. We reanalyzed ARTESIA accounting for competing risks to determine the ARR of apixaban vs. aspirin.

Methods: Individual time-to-event and time-to-censoring data were extracted from the published Kaplan-Meier curve. ARTESIA classified deaths and 24-hour AF events as censoring events. We probabilistically reclassified them to competing events to estimate the ARR accurately. We used the Aalen-Johansen estimator to estimate the cumulative risk of stroke/systemic embolism, accounting for competing events.

Results: After reclassification of deaths and 24-hour AF to competing events, there were 1111 censoring and 852 competing events in the apixaban arm, and 1100 censoring and 816 competing events in the aspirin arm. At 6 years, the ARR was 2.09% (95% CI -0.17 to 4.34) when death and 24-hour AF events were treated as censoring events vs. 1.68% (95% CI 0.46 to 2.89) when they were treated as competing events.

Conclusion: In SCAF, apixaban reduced the 6-year risk of stroke/systemic embolism by 1.68%, a 20% lower benefit when accounting for competing risks. Accounting for competing risks is essential to accurately measure the benefit of anticoagulants for SCAF.

INTRODUCTION

Whether anticoagulants produce a net benefit in people with subclinical atrial fibrillation (SCAF) remains uncertain.[1] When the longest AF episode is <6 minutes, the stroke risk is presumed low, and when it is >24 hours, the risk is high enough that many presume anticoagulants are warranted. However, the benefit is uncertain when the longest episode is between 6 minutes and 24 hours. To answer this question, the Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Subclinical Atrial Fibrillation (ARTESIA) trial randomized people with SCAF between 6 minutes and 24 hours to apixaban or aspirin.[2] The trial demonstrated a relative benefit with apixaban (HR 0.63, 95% CI 0.45–0.88), with an incidence rate reduction of 0.46% per person-year.[2]

Absolute risk reduction (ARR) is a more clinically meaningful measure for guiding treatment decisions;[3,4] however, ARTESIA did not report the ARR. ARTESIA's cumulative incidence plot used a Kaplan-Meier estimator, which does not account for competing events. Additionally, the reported incidence rates also did not account for competing events. A competing event is an outcome that occurs before and precludes the occurrence of the primary outcome.[5] Two competing events—death and >24-hour of AF—were common in ARTESIA, 18% and 24%, respectively. Failing to account for competing risks can overestimate the ARR.[6] In this study, we reanalyzed ARTESIA, accounting for competing events to determine the ARR of apixaban vs. aspirin for stroke prevention in people with SCAF.

METHODS

We used the R package *IPDfromKM* to extract time-to-event and time-to-censoring data from ARTESIA's Kaplan-Meier curve for the composite outcome of stroke/systemic embolism.[7] In

ARTESIA, aside from outcome events, participants were censored at death, 24-hour AF, or administrative reasons like dropout or study end.

Our goal was to estimate the ARR—the difference in cumulative risk of stroke/systemic embolism—accounting for the competing risks of death and 24-hour AF. To accomplish this, we reclassified deaths and 24-hour AF from censoring to competing events. Because the trial did not report which censoring events occurred at each time point, we could not reclassify deaths and 24-hour AF events directly. Instead, we probabilistically reclassified censoring events to competing events using the following approach:

$$Reclassification\ probability_{ay}$$

$$= \frac{\left(At\ risk_{ay} \times ann.death\ probabilty_a \times w_y\right) + \left(At\ risk_{ay} \times ann.24hr\ AF\ probabilty_a\right)}{Total\ censoring\ events_{ay}}$$

The probability that a censoring event in study arm a in study year y was a death or 24-hour AF event, and thus should be reclassified as a competing event ($Reclassification\ probability_{ay}$), equals the number of deaths ($At\ risk_{ay} \times ann.death\ probabilty_a \times w_y$) plus the 24-hour AF events ($At\ risk_{ay} \times ann.24hr\ AF\ probabilty_a$) divided by the total number of censoring events ($Total\ censoring\ events_{ay}$). We obtained the number at risk by study arm and year ($At\ risk_{ay}$), the annual death probability by study arm ($ann.death\ probabilty_a$), and the annual 24-hr AF event probability ($ann.24hr\ AF\ probabilty_a$) from the publication. We obtained the total number of censoring events by study arm and year ($Total\ censoring\ events_{ay}$) using the extracted Kaplan-Meier data. When estimating the number of deaths by study arm and year, we weighted the annual death probability using a Gompertz distribution to reflect the exponential increase in mortality with age (w_y).

We used these probabilities to reclassify censoring events to competing events in the extracted data, repeating the reclassification 1000 times. We validated the extracted data by fitting

a Cox model treating deaths and 24-hour AF as censoring events, mirroring the original analysis. Then, we used the Aalen-Johansen estimator to estimate the cumulative risk of stroke/systemic embolism, treating death and 24-hour AF as competing events.[8] ARR was calculated as the risk difference at 6 years.[9]

RESULTS

The extracted ARTESIA data included 1963 censoring events in the apixaban arm and 1916 in the aspirin arm over a 6-year period. Using these data, we calculated a cause-specific HR (0.63, 95% CI 0.44 to 0.89), which closely matched the trial's report (HR 0.63, 95% CI 0.45 to 0.88).

After reclassification of deaths and 24-hour AF to competing events, there were 1111 censoring and 852 competing events in the apixaban arm, and 1100 censoring and 816 competing events in the aspirin arm, averaged over 1000 iterations. When treating death and 24-hour AF as censoring events, the 6-year cumulative risk of stroke/systemic embolism was 4.35% (95% CI 2.90 to 5.81) with apixaban and 6.44% (95% CI 4.72 to 8.16) with aspirin (**Figure**). When treated as competing events, the cumulative risk of stroke/systemic embolism was 3.18% (95% CI 2.41 to 3.94) with apixaban and 4.86% (95% CI 3.91 to 5.80) with aspirin. At 6 years, the ARR was 2.09% (95% CI -0.17 to 4.34) when death and 24-hour AF were treated as censoring events versus 1.68% (95% CI 0.46 to 2.89) when they were treated as competing events.

DISCUSSION

In this reanalysis of ARTESIA, we estimate the ARR of apixaban over aspirin in SCAF is 1.68% over 6 years when death and 24-hour AF are treated as competing events, lower than the

2.09% ARR implied by the published Kaplan-Meier analysis. As cardiac rhythm monitoring becomes more common and more SCAF is detected, physicians and patients will have to grapple with anticoagulant treatment decisions. As with clinical AF, the expected ARR in stroke/systemic embolism needs to be sufficiently high to warrant anticoagulant harms.

This revised ARR may influence shared decision-making, especially in older adults with higher mortality. Competing risks have a greater impact on those with shorter life expectancies.[10] These findings support broader adoption of competing risks methods to estimate absolute benefit in cardiovascular trials.

Our study has limitations. First, we had to use data extracted from the Kaplan-Meier curve, which may introduce approximation errors in event timing, required us to identify competing events probabilistically, and precluded subgroup analysis. Second, we could not assess how competing risks affect bleeding risk because time-to-bleeding data were unavailable. The effect of a competing risks model will vary depending on the timing of bleeding events.

Reanalysis of the ARTESIA account for competing risks found apixaban reduced the 6-year absolute risk of stroke/systemic embolism by 1.68%, 20% lower than originally implied.

ACKNOWLEDGMENTS

Data sharing: Complete replication of statistical code, including data, is available at:

https://github.com/MGH-DGIM-SHAH/ARTESIA

Ethical review: This analysis uses data that were publicly available prior to initiation of the study. Data can be obtained http://doi.org/10.1056/NEJMoa2310234 (Figure 1). No person-level data were used in this analysis.

Conflict of Interest Disclosure: Dr. Shah reported funding from the National Institute on Aging/National Institutes of Health related to the conduct of this study (noted below). Dr. Singer receives research support from Bristol Myers Squibb-Pfizer and has received consulting fees from Bristol Myers Squibb. Dr. Kim is a consultant to Pfizer. The remaining authors have nothing to disclose.

Funding: This analysis was funded by the NIA (K76AG074919). Dr. Singer was supported, in part, by the Eliot B. and Edith C. Shoolman Fund of the Massachusetts General Hospital.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. Shah SJ. Anticoagulants in Subclinical Atrial Fibrillation: Beginning to Define the Treatment Paradigm. *Journal of the American College of Cardiology*. 2024;84(4):365-367. doi:10.1016/j.jacc.2024.05.015

2. Healey JS, Lopes RD, Granger CB, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. *New England Journal of Medicine*. 2023;0(0):null. doi:10.1056/NEJMoa2310234

3. Elting LS, Martin CG, Cantor SB, Rubenstein EB. Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. *BMJ*. 1999;318(7197):1527-1531. doi:10.1136/bmj.318.7197.1527

4. Nuovo J, Melnikow J, Chang D. Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials. *JAMA*. 2002;287(21):2813-2814. doi:10.1001/jama.287.21.2813

5. Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. *Stat Med*. 2017;36(8):1203-1209. doi:10.1002/sim.7215

6. Austin Peter C., Lee Douglas S., Fine Jason P. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719

7. Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. *BMC Medical Research Methodology*. 2021;21(1):111. doi:10.1186/s12874-021-01308-8

8. Aalen OO, Johansen S. An Empirical Transition Matrix for Non-Homogeneous Markov Chains Based on Censored Observations. *Scandinavian Journal of Statistics*. 1978;5(3):141-150.

9. Gouskova NA, Kundu S, Imrey PB, Fine JP. Number needed to treat for time-to-event data with competing risks. *Statistics in Medicine*. 2014;33(2):181-192. doi:10.1002/sim.5922

10. Shah SJ, van Walraven C, Jeon SY, et al. Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials. *Circ Cardiovasc Qual Outcomes*. Published online March 25, 2024:e010269. doi:10.1161/CIRCOUTCOMES.123.010269

Figure. Cumulative incidence of stroke or systemic embolism in the ARTESIA trial, treating death and 24-hour AF events as either censoring events or competing events

Legend

ARR – absolute risk reduction

The figure displays the cumulative incidence of stroke or systemic embolism by study arm, where death and 24-hour AF events are treated as censoring events (using a Kaplan-Meier estimator, as in Healey et al., NEJM 2024) and as competing events using the Aalen-Johansen estimator. The competing events cumulative incidence line is the average of 1000 datasets where censoring events were probabilistically reclassified as competing events.